Manufactures and sells pharmaceutical products from a facility at Village Haripur, Panchkula, Haryana, generating Rs 147.58 crore in FY26 revenue, up 51% from Rs 97.52 crore the year before. The revenue base is built on third-party manufacturing orders combined with own-brand distribution, with the company investing in distribution channels and brand building during the year. Profitability softened: standalone EBITDA fell to Rs 13.80 crore (margin 9.35%) and standalone PAT slipped to Rs 4.52 crore, while consolidated PAT rose to Rs 5.35 crore. A fire on 27 April 2026 at the Panchkula factory caused Rs 9.39 crore of damage to building, plant, machinery and stocks, with the insurance claim still pending. Capital from a Rs 37.67 crore IPO in June 2025 was partly redirected into a 25.74% stake in Damaira Pharmaceuticals (Rs 6.25 crore) and into a US subsidiary, Astonea LLC in Wyoming, while the company also terminated its agreements with Astonea One Private Limited. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Pharmaceutical manufacturing and sales. Small-cap pharmaceutical manufacturer on BSE SME, growing top line but with margin pressure and a recent uninsured factory fire loss.
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 148 |
| EBITDA (ex other income) | — |
| margin % | — |
| Owners' profit | — |
| EPS, as reported (₹) | 4.49 |
| ROE % · ROCE % | — · 11.3 |
| Debt / equity (x) | — |
| Cash from operations | (14) |
| Capex | (14) |
| ₹ crore | Q4 FY26 |
|---|---|
| Revenue | 81 |
| Profit before tax | 4 |
| Net profit | — |
| EPS (₹) | 3.08 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 9 Sept 2026 · Appointment of Internal Auditor for FY 2026-27 | management changes | medium | — | — |
| 9 Sept 2026 · Board approves new subsidiary, US investment, terminates Astonea One deals | board shareholder meetings | medium | — | — |
| 21 Aug 2026 · Astonea Labs alters Object Clause to expand pharma and healthcare business | general | medium | — | — |
| 21 Aug 2026 · Astonea Labs re-appoints Ms. Pooja Singh as Director at AGM | management changes | medium | — | — |
| 21 Aug 2026 · 9th AGM Voting Results: All 6 Resolutions Approved with 100% Majority | board shareholder meetings | low | — | — |
| 21 Aug 2026 · Astonea Labs 9th AGM held; revenue 148 Cr, PAT 4.51 Cr; 6 resolutions passed | board shareholder meetings | medium | — | — |
| 25 Jul 2026 · Newspaper publication of 9th AGM notice filed with BSE | compliance | minimal | — | — |
| 24 Jul 2026 · Annual Report for Financial Year 2025-26 filed with BSE | compliance | low | — | — |
| 24 Jul 2026 · 9th AGM notice on Aug 21; covers subsidiary investment and MOA change | board shareholder meetings | low | — | — |
| 24 Jul 2026 · Astonea Labs updates tax auditor re-appointment under new Income-tax Act 2025 | management changes | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 93.8 | 28.9 | 153 of 169 | 10% |
| ROCE | 7.2 | 10.8 | 116 of 183 | 37% |
| Market cap | 304 | 839 | 106 of 182 | 42% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
